| Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML (NCT01957644) | Boehringer Ingelheim | 2013-11-06 |
| Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS). (NCT01835587) | Celgene | 2013-10-25 |
| Cohort Study Assessing the Treatment Strategy for High-Risk Myelodysplastic Syndromes in Patients Under 70 (NCT05367583) | University Hospital, Bordeaux | 2013-10-09 |
| Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine (NCT01928537) | Traws Pharma, Inc. | 2013-08-01 |
| Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS) (NCT01822691) | H. Lee Moffitt Cancer Center and Research Institute | 2013-07-01 |
| Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs (NCT01904682) | Traws Pharma, Inc. | 2013-07-01 |
| Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms (NCT01908387) | Celgene Corporation | 2013-07-01 |
| Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome (NCT01892644) | Haukeland University Hospital | 2013-05-01 |
| DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes (NCT00397579) | University of Texas Southwestern Medical Center | 2013-05-01 |
| Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation (NCT01747499) | Washington University School of Medicine | 2013-04-15 |
| Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant (NCT01744223) | Bellicum Pharmaceuticals | 2013-03-01 |
| Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation (NCT01700751) | Washington University School of Medicine | 2013-02-25 |
| Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes (NCT01687400) | Washington University School of Medicine | 2013-02-12 |
| Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT01809392) | The First Affiliated Hospital of Soochow University | 2013-01-01 |
| Biological Predictive Factors of Response to ESA in Low Risk MDS Patients (NCT03598582) | Association pour la recherche sur les Affections Malignes en Immunologie Sanguine | 2013-01-01 |
| Study of Hypotensive Hematopoietic Malignancy Patients' USCOM Readings (NCT01755000) | Washington University School of Medicine | 2012-12-01 |
| CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome (NCT03393611) | Weill Medical College of Cornell University | 2012-11-30 |
| Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) (NCT01736683) | Merck Sharp & Dohme LLC | 2012-11-28 |
| Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms (NCT02084563) | Hospital Israelita Albert Einstein | 2012-10-01 |
| An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands (NCT02891551) | Celgene | 2012-05-01 |
| Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies (NCT02164071) | Celgene | 2012-04-11 |
| Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant (NCT01390311) | Washington University School of Medicine | 2012-04-01 |
| A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes (NCT01571648) | Celgene | 2012-04-01 |
| Empirical Versus Preemptive Antifungal Therapy (NCT01288378) | European Organisation for Research and Treatment of Cancer - EORTC | 2012-03-01 |
| Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine (NCT01519011) | Celgene | 2012-02-07 |
| Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT (NCT01810120) | Mariella Enoc | 2012-01-01 |
| Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants (NCT01488253) | The Korean Society of Blood and Marrow Transplantation | 2012-01-01 |
| An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes (NCT01381809) | Janssen-Cilag International NV | 2011-10-01 |
| Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS (NCT01417767) | Xiao Li | 2011-09-01 |
| Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes (NCT02912208) | Associazione Qol-one | 2011-06-11 |
| Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents (NCT01246076) | Washington University School of Medicine | 2011-06-01 |
| Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors (NCT01158118) | Washington University School of Medicine | 2011-04-01 |
| A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS) (NCT00961064) | National Heart, Lung, and Blood Institute (NHLBI) | 2011-03-15 |
| A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment (NCT02921815) | Celgene | 2011-03-03 |
| High-Tc Susceptometer to Monitor Transfusional Iron Overload (NCT01241357) | Columbia University | 2011-03-01 |
| Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes (NCT01324960) | Groupe Francophone des Myelodysplasies | 2011-03-01 |
| A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS (NCT01085656) | University of Florida | 2011-02-01 |
| Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia (NCT01484015) | Wake Forest University Health Sciences | 2011-02-01 |
| Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (NCT00448201) | UNC Lineberger Comprehensive Cancer Center | 2011-01-07 |
| Follow-up Study of ICUS and CCUS Patients (NCT04428489) | The First Affiliated Hospital of Soochow University | 2011-01-01 |
| Head to Head Comparison of Azacitidine and Decitabine in Myelodysplastic Syndrome (NCT01409070) | Seoul National University Hospital | 2011-01-01 |
| An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome (NCT01400633) | Janssen Korea, Ltd., Korea | 2010-12-01 |
| Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant (NCT01118013) | Alliance for Clinical Trials in Oncology | 2010-12-01 |
| Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts (NCT01241500) | Traws Pharma, Inc. | 2010-11-01 |
| Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) (NCT01201811) | Celgene | 2010-10-01 |
| Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease (NCT00871702) | Washington University School of Medicine | 2010-10-01 |
| Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS) (NCT01065129) | Washington University School of Medicine | 2010-09-02 |
| INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease (NCT01164163) | Children's Oncology Group | 2010-09-01 |
| Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation (NCT01116232) | Barbara Ann Karmanos Cancer Institute | 2010-08-01 |
| A Study of Special Use Results Surveillance of Revlimid 5mg Capsules (NCT02921802) | Celgene | 2010-07-20 |
| MSC and HSC Coinfusion in Mismatched Minitransplants (NCT01045382) | University of Liege | 2010-07-01 |
| Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality. (NCT01718379) | Groupe Francophone des Myelodysplasies | 2010-07-01 |
| Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) (NCT01211457) | Cyclacel Pharmaceuticals, Inc. | 2010-06-17 |
| Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome (MDS) (NCT02428686) | Groupe Francophone des Myelodysplasies | 2010-06-01 |
| Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Myelodysplastic Syndromes (NCT01129739) | Shandong University | 2010-05-01 |
| Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes (NCT02619565) | Assistance Publique - Hôpitaux de Paris | 2010-04-12 |
| Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood (NCT00662090) | University Hospital Freiburg | 2010-04-01 |
| Exjade-Early-Trial (NCT01058369) | University of Erlangen-Nürnberg Medical School | 2010-04-01 |
| Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q (NCT01081431) | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | 2010-03-26 |
| Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q (NCT01088373) | Groupe Francophone des Myelodysplasies | 2010-03-25 |
| Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study (NCT00940602) | Novartis Pharmaceuticals | 2010-03-22 |
| Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer (NCT00963872) | Masonic Cancer Center, University of Minnesota | 2010-03-01 |
| Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome (NCT00946283) | Rutgers, The State University of New Jersey | 2010-03-01 |
| Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant (NCT01077440) | Vanderbilt University | 2010-02-01 |
| Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD (NCT00914940) | Fred Hutchinson Cancer Center | 2009-12-17 |
| A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). (NCT00946647) | Novartis Pharmaceuticals | 2009-12-02 |
| Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant (NCT00986804) | Washington University School of Medicine | 2009-12-01 |
| Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes (NCT00997243) | Alison Walker | 2009-11-01 |
| To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS. (NCT01011283) | Eisai Inc. | 2009-11-01 |
| Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation (NCT00996359) | University of Medicine and Dentistry of New Jersey | 2009-10-01 |
| A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies (NCT01036009) | University of California, San Francisco | 2009-10-01 |
| 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer (NCT00935090) | Barbara Ann Karmanos Cancer Institute | 2009-09-01 |
| Registry of Older Patients With Cancer (NCT01137825) | UNC Lineberger Comprehensive Cancer Center | 2009-09-01 |
| Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer (NCT00949117) | University of South Florida | 2009-09-01 |
| Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes (NCT01674985) | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | 2009-09-01 |
| Pilot Study of Unrelated Cord Blood Transplantation (NCT00916045) | King's College Hospital NHS Trust | 2009-09-01 |
| Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer (NCT01137643) | UNC Lineberger Comprehensive Cancer Center | 2009-07-01 |
| Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome (NCT01009502) | Northwestern University | 2009-07-01 |
| Phase II Cont. IV of ON 01910.Na in MDS w/ Trisomy 8/Intermed-1, 2/High Risk (NCT00987584) | Peter L Greenberg | 2009-06-01 |
| Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes (NCT00923234) | Technische Universität Dresden | 2009-06-01 |
| Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) (NCT00875745) | Indiana University | 2009-04-01 |
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy (NCT00891137) | Cellerant Therapeutics | 2009-04-01 |
| Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative Diseases (NCT00909467) | Medical University of Graz | 2009-04-01 |
| Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer (NCT00726830) | M.D. Anderson Cancer Center | 2009-03-01 |
| Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes (NCT00828802) | Duke University | 2009-03-01 |
| Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant (NCT03961919) | Ciceri Fabio | 2009-02-10 |
| Registry on Hypomethylating Agents in Myeloid Neoplasms (NCT01595295) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2009-02-09 |
| Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA) (NCT01015352) | Groupe Francophone des Myelodysplasies | 2009-02-01 |
| Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer (NCT00823524) | Asan Medical Center | 2009-01-01 |
| A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome (NCT00676728) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2008-12-01 |
| Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT00844441) | Fred Hutchinson Cancer Center | 2008-12-01 |
| Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment (NCT00800150) | City of Hope Medical Center | 2008-11-01 |
| Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers (NCT00952185) | City of Hope Medical Center | 2008-11-01 |
| Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia (NCT00838240) | European Organisation for Research and Treatment of Cancer - EORTC | 2008-11-01 |
| Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes (NCT00809575) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2008-10-02 |
| American Ginseng in Treating Patients With Fatigue Caused by Cancer (NCT00719563) | Alliance for Clinical Trials in Oncology | 2008-10-01 |
| Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer (NCT00782379) | Northside Hospital, Inc. | 2008-10-01 |
| Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) (NCT00854646) | Traws Pharma, Inc. | 2008-10-01 |
| Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder (NCT00755040) | Vanderbilt-Ingram Cancer Center | 2008-10-01 |
| Pathogenesis of Hematologic Malignancies (NCT01728402) | OHSU Knight Cancer Institute | 2008-09-01 |